Company intelligence / Profile preview
Viriom Inc
San Diego, California, United Statesviriom.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Phase 2
01
Overview
Viriom Inc. develops novel therapies and prevention treatments against HIV and hepatitis B. Its lead product, Elpida® (elsulfavirine), a non-nucleoside reverse transcriptase inhibitor, received first market authorization in Russia in June 2017. The company also develops fixed-dose combinations with nucleoside RT inhibitors, an extended-release weekly oral formulation, long acting injectable therapy VM1500A for treatment and PrEP of HIV, as well as a potent tenofovir prodrug targeting both HIV and HBV. Some programs have been discontinued or are inactive.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (e.g., NNRTIs, prodrugs)Long acting injectablesFixed-dose combinations
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships explicitly listed; originator of elsulfavirine was F. Hoffmann-La Roche Ltd.
Beyond the preview
Go deeper on Viriom Inc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viriom Inc.